Analyst: Bavarian's new study design ensures smooth process

New plans for Bavarian Nordic’s phase III study of its Covid-19 booster candidate ease the further development process, allowing for the overall timeline to be maintained despite a slight delay.
Photo: Sven Hoppe/AP/Ritzau Scanpix
Photo: Sven Hoppe/AP/Ritzau Scanpix
by marketwire, translated by daniel pedersen

A redesigned phase III study of Bavarian Nordic’s ABNCoV2, a booster candidate against Covid-19, makes the development process easier while maintaining the overall time plan despite delaying initiation for August, assesses Sydbank analyst Søren Løntoft Hansen.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading